Earnings ·
Annexon, Inc. reported second quarter 2026 financial results and announced key clinical milestones for its…
ANNXAnnexon, Inc.
Annexon, Inc. reported second quarter 2026 financial results and announced key clinical milestones for its neuroinflammatory drug pipeline. The company posted a net loss of $55.3 million, or $0.28 per share, compared to $49.2 million in the prior year period. R&D expenses rose to $46.6 million from $44.2 million, while G&A expenses increased to $10.6 million from $7.6 million. Cash and short-term investments stood at $209.2 million as of June 30, 2026, with an anticipated runway extending into 2028 supported by a new $200 million credit facility. Clinically, the Phase 3 ARCHER II trial for vonaprument in geographic atrophy added a Month 24 dual primary endpoint and launched an open-label extension study; the Month 15 data readout is expected in Q4 2026. Additionally, a BLA submission for tanruprubart in Guillain-Barré syndrome is targeted for Q4 2026. Annexon operates as a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases.